Comparative real-world Progression Free Survival of CDK4/6 Inhibitors in HR+/HER2- Breast Cancer Patients with Bone Metastases

Key Points

• The study aims to compare real-world progression free survival among HR+/HER2- breast cancer patients treated with different CDK4/6 inhibitors.
• Comparative analysis of real-world progression free survival (rwPFS) data.
• Focus on HR+/HER2- metastatic breast cancer patients.
• Evaluation of ribociclib and abemaciclib against palbociclib.
• Ribociclib and abemaciclib show superior rwPFS compared to palbociclib.
• Bone metastases are considered in assessing treatment effectiveness.
• Overall survival (OS) data supports findings of improved outcomes with ribociclib and abemaciclib.